These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 1834746

  • 1. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ, Hillstrom JR.
    J Immunol; 1991 Dec 01; 147(11):4035-44. PubMed ID: 1834746
    [Abstract] [Full Text] [Related]

  • 2. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K.
    J Immunol; 1991 Aug 01; 147(3):1091-7. PubMed ID: 1830596
    [Abstract] [Full Text] [Related]

  • 3. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 4. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J, Demanet C, Moser M, Leo O, Thielemans K.
    J Immunol; 1991 Dec 01; 147(11):4019-26. PubMed ID: 1940384
    [Abstract] [Full Text] [Related]

  • 5. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
    Weiner GJ, Kaminski MS.
    J Immunol; 1990 Mar 15; 144(6):2436-45. PubMed ID: 1690244
    [Abstract] [Full Text] [Related]

  • 6. Immunotherapy with bispecific antibodies.
    Thielemans KM.
    Verh K Acad Geneeskd Belg; 1995 Mar 15; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [Abstract] [Full Text] [Related]

  • 7. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
    Weiner GJ, Kaminski MS.
    J Immunol; 1989 Jan 01; 142(1):343-51. PubMed ID: 2783325
    [Abstract] [Full Text] [Related]

  • 8. In vivo tumor immunotherapy by a bacterial superantigen.
    Ochi A, Migita K, Xu J, Siminovitch K.
    J Immunol; 1993 Sep 15; 151(6):3180-6. PubMed ID: 8376773
    [Abstract] [Full Text] [Related]

  • 9. Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice.
    Weiner GJ.
    Int J Cancer Suppl; 1992 Sep 15; 7():63-6. PubMed ID: 1428408
    [Abstract] [Full Text] [Related]

  • 10. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M, Ochi A.
    J Immunol; 1989 Jun 01; 142(11):4079-84. PubMed ID: 2523940
    [Abstract] [Full Text] [Related]

  • 11. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.
    Cancer Res; 1994 Jun 01; 54(11):2973-8. PubMed ID: 8187084
    [Abstract] [Full Text] [Related]

  • 12. Bispecific antibody therapy of two murine B-cell lymphomas.
    Demanet C, Brissinck J, Moser M, Leo O, Thielemans K.
    Int J Cancer Suppl; 1992 Jun 01; 7():67-8. PubMed ID: 1428409
    [Abstract] [Full Text] [Related]

  • 13. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A, Stevenson GT, Glennie MJ.
    J Immunol; 1991 Jul 01; 147(1):60-9. PubMed ID: 1675655
    [Abstract] [Full Text] [Related]

  • 14. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Jul 01; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

  • 15. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
    Bohlen H, Thielemanns K, Tesch H, Engert A, Wolf HJ, van Camp B, Urbain J, Diehl V.
    Cytokines Mol Ther; 1996 Dec 01; 2(4):231-8. PubMed ID: 9384709
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V, Diehl V, Tesch H.
    Cancer Res; 1993 Sep 15; 53(18):4310-4. PubMed ID: 7689932
    [Abstract] [Full Text] [Related]

  • 20. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.